



## Drug Coverage Policy

Effective Date.....11/1/2024

Coverage Policy Number.....IP0693

Policy Title.....Rytelo

### Hematology – Rytelo

- Rytelo® (imetelstat intravenous infusion – Geron)

#### **INSTRUCTIONS FOR USE**

*The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment and have discretion in making individual coverage determinations. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.*

### Cigna Healthcare Coverage Policy

#### **Overview**

Rytelo, an oligonucleotide telomerase inhibitor, is indicated for the treatment of **transfusion-dependent anemia** in adults with **low- to intermediate-1 risk myelodysplastic syndrome (MDS)** requiring  $\geq 4$  red blood cell units over 8 weeks who have not responded to, have lost response to, or are ineligible for erythropoiesis-stimulating agents (ESAs).<sup>1</sup>

Rytelo was not studied in patients with deletion 5q [del(5q)] cytogenetic abnormalities.<sup>1</sup> Discontinue if a patient does not experience a decrease in red blood cell transfusion burden after 24 weeks of treatment (administration of 6 doses) or if unacceptable toxicity occurs at any time.

## Guidelines

Rytelo is not currently recommended in guidelines.<sup>2</sup> The National Comprehensive Cancer Network guidelines for MDS (version 2.2024 – May 22, 2024) recommend ESAs for the treatment of symptomatic anemia in patients with MDS. Revlimid® (lenalidomide capsules) is also recommended in a variety of clinical scenarios among patients with symptomatic anemia both with and without 5q deletion abnormalities (category 2A). Reblozyl® (luspatercept-aamt subcutaneous injection) is supported for lower-risk disease associated with symptomatic anemia with no del(5q), with or without other cytogenetic abnormalities with ring sideroblasts  $\geq 15\%$  (or ring sideroblasts  $\geq 5\%$  with an SF3B1 mutation) as a single agent (category 1). Treatment with Reblozyl is also supported for lower-risk disease associated with symptomatic anemia with no del(5q), with or without other cytogenetic abnormalities with ring sideroblasts  $< 15\%$  (or ring sideroblasts  $< 5\%$  with an SF3B1 mutation) and serum erythropoietin levels  $\leq 500$  mU/L, as a single agent or following no response to an ESA (despite adequate iron stores) [category 2A]. Data from the Rytelo pivotal study (IMerge) are noted regarding treatment of MDS-related ESA-refractory anemia.

## Medical Necessity Criteria

**Rytelo is considered medically necessary when the following is met:**

**1. Myelodysplastic Syndrome.** Approve for the duration noted if the patient meets ONE of the following (A or B):

- A) Initial Therapy.** Approve for 6 months if the patient meets ALL of the following (i, ii, iii, iv, v, vi, vii and viii):
- i.** Patient is  $\geq 18$  years of age; AND
  - ii.** According to the prescriber, patient has low- to intermediate-1 risk myelodysplastic syndrome (MDS); AND  
Note: MDS risk category is determined using the International Prognostic Scoring System (IPSS).
  - iii.** Patient has transfusion-dependent anemia, defined as requiring transfusion of  $\geq 4$  red blood cell units over an 8-week period; AND
  - iv.** According to the prescriber, patient has not responded, lost response to, or is ineligible for erythropoiesis-stimulating agents; AND  
Note: Examples of erythropoiesis-stimulating agents include an epoetin alfa product (e.g., Epogen, Procrit, or Retacrit), a darbepoetin alfa product (e.g., Aranesp), or a methoxy polyethylene glycol-epoetin beta product (e.g., Mircera).
  - v.** Patient does NOT have deletion 5q [del(5q)] cytogenetic abnormalities; AND
  - vi.** Rytelo will NOT be used in combination with an erythropoiesis stimulating agent; AND
  - vii.** The medication is being prescribed by or in consultation with an oncologist or hematologist; AND
  - viii.** Preferred product criteria is met for the product(s) as listed in the below table(s) OR
- B) Patient is Currently Receiving Rytelo.** Approve for 1 year if, according to the prescriber, the patient has experienced a clinically meaningful decrease in transfusion burden.  
Note: For a patient who has not received 6 months (24 weeks) of therapy or who is restarting therapy, refer to Initial Therapy criteria above.

**Dosing.** Approve up to 7.1 mg/kg by intravenous infusion administered not more frequently than once every 4 weeks.

**Employer Plans:**

Product	Criteria
<b>Rytelo</b> (imetelstat intravenous infusion)	ONE of the following (1, 2 <u>or</u> 3): 1. Patient has tried Reblozyl (luspatercept) 2. Patient meets ALL of the following (A, B, <u>and</u> C): A. Patient does NOT have a deletion 5q [del(5q)]; AND B. Patient has ring sideroblasts < 15% (or ring sideroblasts < 5% with an SF3B1 pathogenic variant); AND C. Patient has tried or has a poor probability to respond to immunosuppressive therapy 3. Patient has already been started on therapy with Rytelo

**Individual and Family Plans:**

Product	Criteria
<b>Rytelo</b> (imetelstat intravenous infusion)	ONE of the following (1, 2 <u>or</u> 3): 1. Patient has tried Reblozyl (luspatercept) 2. Patient meets ALL of the following (A, B, <u>and</u> C): A. Patient does NOT have a deletion 5q [del(5q)]; AND B. Patient has ring sideroblasts < 15% (or ring sideroblasts < 5% with an SF3B1 pathogenic variant); AND C. Patient has tried or has a poor probability to respond to immunosuppressive therapy 3. Patient has already been started on therapy with Rytelo

When coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy.

Receipt of sample product does not satisfy any criteria requirements for coverage.

## Conditions Not Covered

Any other use is considered experimental, investigational, or unproven (criteria will be updated as new published data are available).

## References

1. Rytelo® intravenous infusion [prescribing information]. Foster City, CA: Geron; June 2024.
2. The NCCN Myelodysplastic Syndromes Clinical Practice Guidelines in Oncology (version 2.2024 – May 22, 2024). © 2024 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on June 7, 2024.

## Revision Details

Type of Revision	Summary of Changes	Date
New	New policy	10/1/2024
Selected Revision	<b>Preferred Product Table:</b>	11/1/2024

	<b>Added</b> a prerequisite step through Reblozyl prior to coverage of Rytelo, for both Employer and Individual and Family Plans.	
--	---	--

The policy effective date is in force until updated or retired.

---

“Cigna Companies” refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2024 The Cigna Group.